Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28548757 | 0.98 | TSHR (0.52) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL1098601 | 0.86 | TSHR (0.58) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL19402824 | 0.85 | TSHR (0.56) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL19784710 | 0.83 | TSHR (0.57) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL30200780 | 0.83 | TSHR (0.54) | TSHRCA12CA14KMT2ALMNA | |
| SCHEMBL1403393 | 0.83 | TSHR (0.54) | TSHRCA12CA14KMT2ALMNA | |
| SCHEMBL1403149 | 0.83 | TSHR (0.54) | TSHRCA12CA14KMT2ALMNA | |
| SCHEMBL19784553 | 0.81 | TSHR (0.55) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL1968935 | 0.78 | TSHR (0.57) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL4374105 | 0.78 | TSHR (0.57) | TSHRCA12CA14KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806532-A | Preparation method of impurities in MIT | 大连百傲化学股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4146651-B1 | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS | NINGXIA ACADEMY AGRICULTURE & FORESTRY SCIENCES (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4638441-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12410166-B2 | Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2025-09-09 | — | — | US | disclosed |
| EP-4157845-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-0698600-A1 | Composition, method and test device for determining the presence of leukocyte cells, esterase or protease in a test sample | Bayer Corporation (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5464739-A | Urinalysis, hydrolysis of lactate ester | BAYER CORPORATION (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0447013-B1 | Fluorobenzene sulphonamides | SCHERING AG (DE) | 1994-08-03 | — | — | EP | disclosed |
| US-5210290-A | NMR diagnostic aid | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-05-11 | — | — | US | disclosed |
| EP-0447013-A1 | Fluorobenzene sulphonamides | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0015442-B1 | LOW-FOAMING CORROSION INHIBITORS WITH MICROBIOCIDAL PROPERTIES, THAT CONTAIN ALCANOLAMINE-BORIC ACID REACTION PRODUCTS AS THE ACTIVE INGREDIENTS | BASF Aktiengesellschaft (DE) | 1982-03-24 | — | — | EP | disclosed |
| US-4267122-A | USEFUL AS CORROSION INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| EP-0015442-A1 | Low-foaming corrosion inhibitors with microbiocidal properties, that contain alcanolamine-boric acid reaction products as the active ingredients | BASF Aktiengesellschaft (DE) | 1980-09-17 | — | — | EP | disclosed |
| US-4126634-A | CORROSION INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1978-11-21 | — | — | US | disclosed |
| US-4060522-A | ANTICORROSIVE | BASF AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | TSHR 2894/4885CA12 4240/4885CA14 3614/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | TSHR 2641/4885CA12 4596/4885CA14 4673/4885 |
| US-12410166-B2 | Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors | MGAM, MGAM2, ABCC1 | TSHR 2534/4885CA12 3565/4885CA14 3658/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | TSHR 3789/4885CA12 4528/4885CA14 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.